We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00406900
Recruitment Status : Unknown
Verified November 2006 by Ludwig-Maximilians - University of Munich.
Recruitment status was:  Recruiting
First Posted : December 4, 2006
Last Update Posted : December 6, 2006
Information provided by:

Study Description
Brief Summary:
Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Melanoma inhibitory activity" is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients

Condition or disease Intervention/treatment
Melanoma Radiotherapy Metastatic Disease Procedure: Treatment of metastatic disease

Detailed Description:
Serum is taken from each melanoma patient at every follow up after signed concent. With ELISA the marker MIA is evaluated. An increase of MIA serum level will lead to search for metastasis by oncologists.

Study Design

Study Type : Observational
Estimated Enrollment : 560 participants
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Study Start Date : January 1999
Estimated Study Completion Date : September 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • uveal melanoma (With/without overt metastatic disease)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00406900

Contact: Ulrich C Schaller, MD +49/89/5160 ext 3811 ulrich.schaller@med.uni-muenchen.de

Dept of Ophthalmology, University of Munich Recruiting
Munich, Germany, 80538
Contact: Ulrich C Schaller, MD    +49895160 ext 3811    ulrich.schaller@med.uni-muenchen.de   
Principal Investigator: Ulrich C Schaller, MD         
Sponsors and Collaborators
Ludwig-Maximilians - University of Munich
Principal Investigator: Ulrich C Schaller, MD University of Munich, Germany
More Information

ClinicalTrials.gov Identifier: NCT00406900     History of Changes
Other Study ID Numbers: MIA
First Posted: December 4, 2006    Key Record Dates
Last Update Posted: December 6, 2006
Last Verified: November 2006

Keywords provided by Ludwig-Maximilians - University of Munich:
uveal melanoma
metastatic disease

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplasms, Second Primary
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplastic Processes
Pathologic Processes